Neuraxis Inc
NRXS3.900USD
+1.630+71.81%
Close 05/20, 16:00（ET）Quotes delayed by 15 min
28.14MMarket Cap
LossP/E TTM
More Details of Neuraxis Inc Company
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Company Info
Company codeNRXS
Company nameNeuraxis Inc
IPO dateAug 09, 2023
Founded at2022
CEOMr. Brian Carrico
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address11611 N. Meridian St
CityCARMEL
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code46032
Phone18126890791
Websitehttps://neuraxis.com/
Company codeNRXS
IPO dateAug 09, 2023
Founded at2022
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1.11K%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Ms. Beth Keyser
Ms. Beth Keyser
Independent Director
Independent Director
--
--
Mr. Gil Aharon
Mr. Gil Aharon
Director
Director
--
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
--
-100.00%
Mr. Bradley Mitch Watkins
Mr. Bradley Mitch Watkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1.11K%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Brown (Christopher Robin)
10.99%
Hannasch (Brian)
10.75%
Creative Planning, Inc.
7.65%
Masimo Corp
7.37%
Parsons Capital Management, Inc.
1.62%
Other
61.63%
Shareholder Statistics
Shareholder
Proportion
Brown (Christopher Robin)
10.99%
Hannasch (Brian)
10.75%
Creative Planning, Inc.
7.65%
Masimo Corp
7.37%
Parsons Capital Management, Inc.
1.62%
Other
61.63%
Type
Shareholder
Proportion
Individual Investor
22.97%
Investment Advisor/Hedge Fund
8.74%
Corporation
7.37%
Investment Advisor
1.86%
Bank and Trust
1.48%
Hedge Fund
0.40%
Private Equity
0.28%
Other
56.92%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
30
4.17M
57.80%
+470.52K
2024Q4
29
4.04M
56.27%
+476.54K
2024Q3
28
3.89M
54.36%
+476.60K
2024Q2
27
3.62M
51.12%
+229.93K
2024Q1
18
1.89M
32.23%
+1.25M
2023Q4
18
2.14M
36.50%
+1.56M
2023Q3
14
2.07M
34.17%
+2.07M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Brown (Christopher Robin)
792.84K
10.99%
--
--
Jun 17, 2024
Hannasch (Brian)
682.90K
9.46%
+133.33K
+24.26%
Sep 30, 2024
Masimo Corp
531.55K
7.37%
--
--
Jun 17, 2024
Parsons Capital Management, Inc.
116.73K
1.62%
+103.73K
+797.89%
Dec 31, 2024
BMO Harris Bank N.A.
139.02K
1.93%
-10.00K
-6.71%
Dec 31, 2024
The Vanguard Group, Inc.
27.98K
0.39%
--
--
Dec 31, 2024
Citadel Advisors LLC
47.09K
0.65%
+47.09K
--
Dec 31, 2024
Stifel, Nicolaus & Company, Incorporated
25.71K
0.36%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
22.70K
0.31%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
